The report highlights that 81% of organizations plan to amplify their outsourcing efforts in the next three to five years.

With high stakes on R&D investment, fierce competition for speed-to-market, and the new Biosecure Act, biopharma’s Procurement and Outsourcing teams face mounting pressure to deliver.